# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, ...
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $204 t...
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $238 to $251.
ResMed reported Q4 2024 revenue of $1.22 billion, driven by strong demand for sleep devices and software services. Gross margin...
Needham analyst Mike Matson reiterates ResMed (NYSE:RMD) with a Buy and maintains $236 price target.